Altimmune, Inc.

ALT
$2.91 (- $0.02 - 0.68%)
Last updated: 2026-06-24 11:52 UTC
ALT Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS02155H2004
CUSIP02155H200
Market Price2.91
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.07
Market Cap$417.4M
Book Value1.94
Price to Book2.061
Beta-0.04
52w High8.05
52w Low2.9
Next Earnings DateN/A

Altimmune, Inc. trades under ticker ALT on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US02155H2004, CUSIP 02155H200.

About the Company
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Price History